Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.J&J calls back paediatric drugs Benadryl tablets, Motrin
Bloomberg has quoted J&J spokesperson Bonnie Jacobs as saying that when the manufacturing process was developed, it was not done as thoroughly as it should have been. "There
Bloomberg has quoted J&J spokesperson Bonnie Jacobs as saying that when the manufacturing process was developed, it was not done as thoroughly as it should have been. "There
According to ShangPharma, the revenue rises primarily due to a larger customer base, higher revenues from the company’s top customers, broader service offerings and higher average rate from
Orban Biotech said that the QTDP covers funding for a therapeutic insulin B chain vaccine to treat type 1 diabetes mellitus. The company claims that its insulin B
Apricus Bio said that Vitaros incorporates alprostadil, a well-recognised vasodilator that is currently marketed as an injectable product or an intra-urethral insert product for patients with erectile dysfunction.
Discovered and developed by Eisai, Halaven is a non-taxane, microtubule dynamics inhibitor and a synthetic analog of halichondrin B, a natural product isolated from the marine sponge Halichondria
China Shenghuo Pharmaceutical is a specialty pharmaceutical company that focuses on the manufacture, research, development and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. China
MedQuist is a provider of integrated clinical documentation solutions for the US healthcare industry. MedQuist’s operating income was $13.29m, compared to $8.12m for the comparable period in 2009.
Inviragen’s DENVax vaccine, developed by researchers at the CDC’s Division of Vector-Borne Diseases, is based on an attenuated DEN-2 virus that generates long-lasting anti-dengue immune responses. The Colombian
Together they will cover recent relocation projects, the benefits of Triangle Park in North Carolina and the all important $1bn Investment Novartis has made in the region, to
As per the terms of the agreement, Novartis is expected to pay a $45m upfront fee to ImmunoGen for exclusive rights to use ImmunoGen’s Targeted Antibody Payload (TAP)